A total of 16 and 30 cell lines were defined as sensitive and resistant, respectively (Table 1).
Those with log10 (GI50) at least 0.5 SDs below the mean were defined as sensitive to the drug.
Therefore, 30 samples (30.00% of all) were defined as sensitive to irinotecan, and 72 samples (70.00% of all) were defined as resistent, compared to untreated controls.
The strain was declared resistant to the specific drug; or it was defined as sensitive when the growth rate was < 1% compared to the control.
Of 262 tumours, 123 (47%) were identified as non-sensitive to all tested therapies (RA), whereas 24 (9%) were defined as sensitive to all tested therapies (SA); the remainder (44%) were sensitive to at least one therapy.
Individuals with a score of > 20 were defined as sensitive to common chemicals (cases) while individuals with moderate or no symptoms were classified as non-sensitive (controls, ≤ 20 scores).
In the Ames assay, a strain was defined as sensitive if there was a reproducible demonstration of concentration-related effects with a 2-fold increase in the number of revertants over the spontaneous frequency of revertants.
Then, cell lines with IC50 at least 0.8 SDs above the mean were defined as resistant, whereas those at least 0.8 SDs below the mean were defined as sensitive.
A low-risk score (1 – 3 ) for this element is defined as "no evidence of clinically relevant resistance to any of the antiviral drugs approved for human use (neuraminidase inhibitors and M2 blockers)." A moderate-risk score (4 – 7 ) is defined as "sensitive to all neuraminidase inhibitors but resistant to M2 blockers".
For each drug, cell lines with normalized activity area at least 0.8 standard deviations (SDs) above the mean were defined as sensitive to the compound, whereas those with activity area at least 0.8 SDs below the mean were defined as resistant.
